Xiao-ke Guo

Jiang Su Key Laboratory Of Drug Design And Optimization And State Key Laboratory Of Natural Medicines
Nanjing, 210009, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity.

Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity.

Journal: Journal of medicinal chemistry
Published: May 01, 2025

Discovery of the salicylaldehyde-based compound DDO-02267 as a lysine-targeting covalent inhibitor of ALKBH5.

Discovery of the salicylaldehyde-based compound DDO-02267 as a lysine-targeting covalent inhibitor of ALKBH5.

Journal: European journal of medicinal chemistry
Published: October 30, 2024

Discovery of Pyrazolo[1,5-a]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML.

Discovery of Pyrazolo[1,5-a]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML.

Journal: Journal of medicinal chemistry
Published: November 20, 2023

Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.

Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.

Journal: European journal of medicinal chemistry
Published: October 19, 2019

Design, synthesis, and initial evaluation of affinity-based small molecular probe for detection of WDR5.

Design, synthesis, and initial evaluation of affinity-based small molecular probe for detection of WDR5.

Journal: Bioorganic chemistry
Published: September 15, 2017

Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.

Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.

Journal: Bioorganic & medicinal chemistry
Published: September 05, 2017

Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.

Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.

Journal: Bioorganic & medicinal chemistry
Published: August 31, 2016

Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.

Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.

Journal: Bioorganic & medicinal chemistry
Published: August 19, 2016

High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.

High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.

Journal: European journal of medicinal chemistry
Published: May 09, 2016

G9a - An Appealing Antineoplastic Target.

G9a - An Appealing Antineoplastic Target.

Journal: Current cancer drug targets
Published: January 26, 2016

Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor.

Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor.

Journal: Journal of medicinal chemistry
Published: August 11, 2015

Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.

Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.

Journal: European journal of medicinal chemistry
Published: July 22, 2015
Showing 1-12 of 23

Last Updated: 09/26/2026